Skip to main content

Table 1 Characteristics of the study cohort

From: A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

Characteristic Dementia of the Alzheimer type Dementia due to other reasons p value
Number 23 17  
Gender (male/female) 10/13 12/5 0.116*
Age (years) 69.0 ± 10.9 64.4 ± 11.0 0.199**
MMSE 22.6 ± 4.4 25.3 ± 2.4 0.041**
CDT (points) 3.0 ± 1.3 2.4 ± 1.2 0.147**
CSF Aβ1–40 (ng/ml) 11.87 ± 3.67 (n = 21) 10.08 ± 3.43 (n = 15) 0.147**
CSF Aβ1–42 (ng/ml) 0.59 ± 0.15 (n = 22) 1.20 ± 0.28 (n = 15) < 0.0001**
CSF Aβ42/40 ratio 0.052 ± 0.18 (n = 21) 0.126 ± 0.30 (n = 15) < 0.0001**
CSF tTau (pg/ml) 731.6 ± 283.6 (n = 22) 300.8 ± 116.5 (n = 15) < 0.0001**
CSF pTau (pg/ml) 85.1 ± 32.0 (n = 22) 42.5 ± 12.2 (n = 15) < 0.0001**
  1. Data presented as mean ± standard deviation, unless otherwise stated
  2. amyloid beta, CDT clock-drawing test, CSF cerebrospinal fluid, MMSE Mini-Mental State Examination, pTau phosphorylated Tau protein, tTau total Tau protein
  3. *Fisher’s exact test
  4. **Unpaired t test for differences between the two diagnostic categories